Scandinavian Real Heart AB
Scandinavian Real Heart AB develops and commercializes medical devices for cardiac care, primarily generating revenue through product sales and service contracts.
Business. Scandinavian Real Heart AB (HEART.ST) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, with key performance indicators including organic revenue growth, procedure volume, and gross margin. Headquarters and specific operating segment details are not provided in the available data. The company is primarily listed on the Nasdaq Stockholm exchange.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Scandinavian Real Heart AB (HEART.ST) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, with key performance indicators including organic revenue growth, procedure volume, and gross margin. Headquarters and specific operating segment details are not provided in the available data. The company is primarily listed on the Nasdaq Stockholm exchange.
The company's capital structure is characterized by a low debt-to-equity ratio of 0.07, indicating a conservative leverage approach. However, the negative operating and net income of -35.5 million SEK and -35.5 million SEK respectively, combined with a negative free cash flow of -63.6 million SEK, suggest significant liquidity pressure. The price-to-book ratio of 2.45 implies that the market is valuing the company at a premium to its book value, despite the negative returns on equity and assets of -56.8% and -48.8% respectively. This premium may reflect expectations of future profitability or market share gains, but current financial performance does not support such optimism.
Profitability metrics are well below industry norms, with the company reporting negative returns on both equity and assets. The return on equity of -56.8% and return on assets of -48.8% indicate that the company is not generating returns that cover its cost of capital, which is a critical concern for investors. The industry_config for medical equipment typically emphasizes EBITDA margins and operating cash flow as key performance indicators, both of which are negative for Scandinavian Real Heart AB. This suggests that the company is not only failing to meet industry benchmarks but is also at risk of further financial deterioration if operational improvements are not made.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks, such as regulatory changes or economic downturns in the primary operating region. The absence of segment or geographic breakdown in the financial data limits the ability to assess the company's exposure to different markets and product lines, which is a concern for investors seeking to understand the sources of risk and growth potential.
The company's growth trajectory is uncertain, with no disclosed revenue growth in the most recent financial period. The outlook for the current fiscal year does not provide specific numeric deltas, but the negative operating and net income suggest that the company is not on a path to profitability in the near term. The capital expenditure of -28.3 million SEK indicates ongoing investment in the business, but without corresponding revenue growth, these expenditures may not yield the desired returns. The company's ability to achieve positive cash flow and profitability will be critical to its long-term viability.
The risk assessment highlights medium liquidity risk and low dilution risk. The negative free cash flow and negative operating cash flow of -63.6 million SEK and -15.7 million SEK respectively, combined with a current ratio of 2.5, suggest that the company has sufficient short-term assets to cover its liabilities but is not generating positive cash flow from operations. The dilution risk is low, as the number of shares outstanding has not changed between basic and diluted shares, indicating no imminent threat from share issuance. However, the company's negative net cash position after subtracting total debt is a key flag that warrants further investigation.
Recent events, including filings and transcripts, are not disclosed in the available data, which limits the ability to assess the company's strategic direction and management's response to financial challenges. The absence of recent events or disclosures may indicate a lack of transparency or a focus on internal operations rather than public communication. Investors should monitor future filings and management statements for insights into the company's financial health and strategic initiatives.
- The company is operating at a loss with negative returns on equity and assets, indicating poor profitability.
- The low debt-to-equity ratio suggests a conservative capital structure, but the negative free cash flow indicates liquidity pressure.
- Revenue concentration in a single segment and lack of geographic diversification increase business risk.
- The company's growth trajectory is uncertain, with no disclosed revenue growth and negative operating and net income.
- The risk assessment highlights medium liquidity risk and low dilution risk, but the negative net cash position is a key concern.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Scandinavian Real Heart AB Market data — financials · 2026-05-28